Lupus Erythematosus clinical trials

Explore recruiting lupus erythematosus clinical trials.

Recruiting lupus erythematosus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lupus Erythematosus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus

France, Poland, Italy, Czechia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of anifrolumab on cutaneous lupus erythematosus characterized by the change of the inflammatory infiltrate analyzed by immunohistochemistry, spatial transcriptomics and single-cell RNA- and TCR-sequencing as well as on the clinical outcome - an open label, single arm phase IV pilot study

Austria

Therapeutic use (Phase IV) EU CTIS Study details

OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

Spain, Germany, Portugal, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

Bulgaria, Romania, Germany, Spain, Hungary, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Romania, Germany, Hungary, Netherlands, Czechia, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus: A randomized, double blind, placebo-controlled, Phase 2, proof of concept study.

Spain, Greece, Italy, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

Lupus Erythematosus trials by city

Lupus Erythematosus in Toronto Lupus Erythematosus in Vancouver Lupus Erythematosus in Montreal Lupus Erythematosus in Calgary Lupus Erythematosus in Edmonton Lupus Erythematosus in Ottawa Lupus Erythematosus in Winnipeg Lupus Erythematosus in Quebec City Lupus Erythematosus in Hamilton Lupus Erythematosus in Kitchener Lupus Erythematosus in London Lupus Erythematosus in Halifax Lupus Erythematosus in New York Lupus Erythematosus in Los Angeles Lupus Erythematosus in Chicago Lupus Erythematosus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease